72 results about "Tumor removal" patented technology

The utility model discloses a tumor electric field treatment device and a treatment system, the tumor electric field treatment device is provided with a frame body and a pole piece module, the frame body forms a skeleton structure of the treatment device, the pole piece module is attached to the frame body, the pole piece module is provided with a plurality of electrode contacts, and each electrode contact can form an active contact or a passive contact. The active contact and the radio frequency generation module can form a loop; after the treatment device is implanted into a tumor excision part, all the electrode contacts form active contacts, and all the electrode contacts and the radio frequency generation module form a loop to distinguish normal tissues from pathological tissues; after the normal tissue and the lesion tissue are distinguished, the electrode contacts in the normal tissue area form passive contacts, and the electrode contacts in the lesion tissue area form active contacts, so that targeted treatment of the lesion tissue is realized, and side effects generated by electric field treatment are reduced.

The invention discloses a navigation system for a liver tumor resection operation, and aims to solve the problems that in the prior art, the accuracy of the liver tumor resection operation is insufficient, the risk in the operation is high, and the evaluation after the operation is incomplete. The system comprises a preoperative data acquisition module, a preoperative three-dimensional modeling module, an intraoperative positioning module, an operation navigation module, a risk prompt module and a postoperative data analysis module. Through preoperative CT or MRI image data acquisition, automatic segmentation and three-dimensional reconstruction of liver, tumor and blood vessels are carried out by using a deep learning algorithm, and a high-precision anatomical model is generated. During the operation, the position of the surgical instrument is obtained in real time by using an optical tracking or electromagnetic positioning technology, spatial precise alignment of the surgical instrument with a tumor and surrounding tissues is realized in combination with a model registration algorithm, and a surgical path is displayed through a real-time navigation interface. And the risk prompting module calculates an excision risk coefficient and prompts a doctor in real time based on the shortest distance between the tumor and the blood vessel, the relative distance between the instrument and the target area and the trajectory change.

The invention relates to an estrogen receptor alpha and fibroblast activating protein dual-targeting near-infrared fluorescent probe as well as a preparation method and medical application thereof. Specifically, the probe can be used as a fluorescence probe for developing cells co-expressing the estrogen receptor alpha and the fibroblast activating protein, and can also be used as a near-infrared fluorescence imaging probe for diagnosing benign / malignant lesions such as nodules / tumors co-expressing the estrogen receptor alpha and the fibroblast activating protein. The fluorescent probe can also be applied to research on related biological events in cells for co-expressing the estrogen receptor alpha and the fibroblast activating protein, and particularly can be applied to fluorescent navigation in tumor resection operations for co-expressing the estrogen receptor alpha and the fibroblast activating protein; particularly, the composition can be applied to the synergistic treatment of an anti-estrogen therapy and a photodynamic therapy on a diseased region which co-expresses the estrogen receptor alpha and the fibroblast activating protein.

The present invention provides a hydrogen sulfide-activated near-infrared II small molecule optical diagnostic and therapeutic agent, whose chemical structure is: [Illegible text - likely a missing link]. This diagnostic and therapeutic agent can accurately identify solid tumors overexpressing hydrogen sulfide, effectively distinguishing tumors from normal tissue, and can be used for tumor resection under the guidance of NIR-II fluorescence imaging. Furthermore, it has excellent photothermal conversion efficiency and can successfully ablate tumors under laser irradiation. This agent demonstrates significant advantages in tumor identification and treatment and is expected to become a highly effective molecular tool for tumor diagnosis and treatment.

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.

The invention relates to the technical field of tumor extraction in vitro, and particularly discloses a tumor bagging and cutting device for an operation. The tumor bagging and cutting device for the operation comprises an inner memory wire, an outer memory wire, an inner-layer bag, an outer-layer bag, a core tube, a plurality of first-direction cutting ropes and a plurality of second-direction cutting ropes. An inner ring cavity is formed in a bag opening of the inner-layer bag. The inner memory wire rod is arranged in the inner ring cavity in a penetrating mode, and the two ends of the inner memory wire rod penetrate into the core tube. An outer ring cavity is formed in a bag opening of the outer-layer bag. The outer memory wire rod is arranged in the outer ring cavity in a penetrating mode. The middle section of the first-direction cutting rope and the middle section of the second-direction cutting rope are both located in the inner-layer bag. And for the cut tumor which is still in the human body, the tumor is put into the inner-layer bag, the tumor is cut by using the first-direction cutting rope and the second-direction cutting rope, and the cut tumor is taken out after being cut into small strips. The tumor linear cutting mode is high in safety coefficient. The inner-layer bag protects the outer-layer bag, so that the chopped tumor does not leak out of the outer-layer bag, and the safety is improved.

The present application relates to providing a doxorubicin-loaded anti-tumor hemostatic microsphere constructed by a simple, safe and low-cost method and its preparation and application, the doxorubicin-loaded anti-tumor hemostatic microsphere comprises alginate, hemostatic component A, doxorubicin or doxorubicin liposome, crosslinking agent, the hemostatic component A is selected from one or more of carboxymethyl chitosan, hyaluronic acid, collagen, silk fibroin, solve the practical pain point problems such as easy bleeding in tumor resection surgery, large toxicity of chemotherapeutic drugs, large drug dose, frequent drug administration, etc., realize rapid hemostasis in operation, postoperative precise targeted drug delivery, reduce toxic side effects, long-acting drug sustained release, at the same time, all components of the system are safe and reliable, and have good biocompatibility.

The invention relates to a compound as shown in a formula (I) and / or a formula (II) and / or a formula (III) or a tautomer or pharmaceutically acceptable salt thereof, a preparation method and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicine. Specifically, the fluorescent probe can be used as a fluorescent probe for cytological imaging, can also be used as a near-infrared fluorescent imaging probe for diagnosing benign / malignant lesions such as fibrosis, nodules and tumors, and can also be applied to research of related biological events in cytobiology and molecular biology. The fluorescent probe can be particularly applied to fluorescent navigation in tumor resection surgery.

The invention relates to the technical field of operating forceps, and discloses gynecological tumor removal operating forceps which comprise an outer rod, an inner rod movably connected to the interior of the outer rod, a first handle fixedly connected to the outer end of the inner rod and a connecting assembly arranged between the outer rod and the inner rod. A limiting mechanism is arranged between the first handle and the inner rod, the top end of the first spring is fixedly connected with the second clamping rod, the outer side of the positioning block is fixedly connected with the mounting base, the slope clamping block movably penetrates through the movable groove and is clamped with the clamping groove, one end of the second spring is fixedly connected with the movable block, and a movable hole is formed in the outer side of the inner wall of the movable groove. And a pull rod is movably connected into the movable hole. The problems that when an existing device is used, a clamping rod is inconvenient to replace, and after the clamping rod is damaged and deforms, the whole operating forceps are scrapped, so that resource loss is caused are solved.

The application belongs to the technical field of medical auxiliary devices, and is especially an endoscopic foreign body and tumor removal device, which comprises a gastroscope tube, an outer protective tube and a clamping tube. The outer protective tube is sleeved on the outside of the gastroscope tube, and the clamping tube is arranged in the inside of the gastroscope tube. The rear end of the clamping tube is fixedly connected with a control handle. The inside of the control handle is screw-connected with a T-shaped screw rod. The front end of the control handle is connected with a sliding block through a rotating shaft, and the sliding block is slidingly connected with the control handle. The front end of the sliding block is fixedly connected with a main control line, and the front end of the main control line extends to the inside of the front end of the clamping tube. The front end of the main control line is connected with a branch line one and a branch line two respectively. The application can clamp foreign bodies or circular pathological tissues, and the foreign bodies or circular pathological tissues can be covered by the semicircular clamping sleeve one and the semicircular clamping sleeve two, so that the foreign bodies or circular pathological tissues are not easy to fall off during the clamping and removal process, and the application is better.

This utility model discloses a bipolar radiofrequency electrode for bone tumor surgery, which includes a cable assembly, a handle, a scalpel, and a scalpel head connected in sequence. The scalpel head includes a suction tube and an outer steel tube that is spaced and sleeved on the suction tube, with a water outlet channel formed between the suction tube and the outer steel tube. The scalpel head includes an insulating head fixed to the distal end of the outer steel tube. The insulating head is provided with a first strip electrode and a second strip electrode arranged side by side. The insulating head located at the first strip electrode and the second strip electrode has several suction holes, which are connected to the suction tube. Several water outlet holes connected to the water outlet channel are provided on both sides of the distal end of the outer steel tube. This solution uses radiofrequency electrodes to irrigate the incision after the resection of benign spinal tumors, which can accurately stop bleeding at soft tissue bleeding points, effectively reducing the amount of bleeding. Furthermore, by utilizing the circulating supply of physiological saline, the first strip electrode and the second strip electrode are effectively wrapped by physiological saline, thereby ensuring the plasma excitation efficiency.

A neurosurgical method for determining a resection status of a tumor is described. The method includes acquiring a medical image of a human organ including a segmented tumor. The method further includes determining a pose of a suction tool including at least one optical fiber and a navigation tracker. The method further includes generating excitation light for the at least one optical fiber to excite the target area which includes the tumor and a margin area surrounding the tumor. The method further includes receiving collected fluorescence emitted from the target area. The method further includes determining whether tissue in the target area corresponds to the tumor based on the collected fluorescence at the pose of the suction tool. The method further includes displaying the resection status of the target area relative to the medical image.

A method for treating tumor cells around a resection cavity comprises positioning a nonconductive material within a resection cavity that is adjacent to a target region. At least a first electrode and a second electrode are positioned relative to the tumor resection cavity so that electric fields between the at least one first electrode and the at least one second electrode travel through the target region. Tumor-treating electric fields are the generated between the at least one first electrode and the at least one second electrode.

The invention belongs to the technical field of medical image processing, and discloses a tumor resection operation planning method and system based on a 3D model, and a storage medium. The method comprises the following steps: obtaining a first medical image and a second medical image, and extracting all blood vessel branch structures in a target organ in each medical image, registering the first medical image and the second medical image based on a common branch structure, generating a third medical image, extracting a tumor area and a blood supply branch connected with the tumor, calculating the shortest distance from the center point of the tumor to the outer surface of the target organ, judging whether the shortest distance is smaller than a first preset value or not, if yes, generating a first surgical area, and if not, generating a second surgical area; and if not, generating a second surgical area, and planning a planned resection range and a surgical approach based on the surgical area. According to the technical scheme, the accuracy and the success rate of the operation can be improved.

A method for treating tumor cells around a resection cavity comprises positioning a nonconductive material within a resection cavity that is adjacent to a target region. At least a first electrode and a second electrode are positioned relative to the tumor resection cavity so that electric fields between the at least one first electrode and the at least one second electrode travel through the target region. Tumor-treating electric fields are the generated between the at least one first electrode and the at least one second electrode.

The invention discloses an intelligent image recognition method in a fluorescence state, and relates to the technical field of medical equipment, and the method comprises the following steps: collecting a fluorescence image and a white light image at the same time point through 4K fluorescence endoscope camera equipment, and carrying out the image preprocessing, including illumination correction, fuzzy correction, filtering and denoising, and edge enhancement; based on a Mask RCNN algorithm, performing intelligent identification on a tumor boundary in the fluorescence image, and identifying the tumor boundary in the fluorescence image; performing spatial alignment on the fluorescent image and the white light image through an image registration technology; based on a GAN algorithm, fusing the identified tumor boundary with the white light image to generate a high-precision fused image; automatically marking a safe cutting edge in the white light image according to a preset safe cutting edge distance; and finally, displaying the marked white light image in real time to assist a doctor in tumor excision. According to the invention, the operation burden of a doctor in image switching is reduced, and the accuracy of an operation is improved.

According to the invention, in order to remove tissue, in particular pathogenic tissue, from a body cavity of a patient, a removal device is provided having a removal bag (12) which is completely or partially composed of a hydrophilic, water-permeable filter membrane (26). The filter membrane (26) comprises a pore width of preferably less than 12 pm, further preferably less than 8 pm and in a preferred case less than 5 pm, in order to reliably avoid the passage of pathogenic cells or other pathogenic material. However, the pores are at least large enough so that water can easily exit from the removal bag (12). In this way, the removal bag (12) only needs to be occupied by the volume of the contained tissue to be removed in the filled state. The liquid provided within the removal bag (12) can be drained from the removal bag through the filter membrane (26) and thus does not increase its volume. This allows relatively large tissue masses to be accommodated during tumor removal. Thus, tumors can be removed as a whole without having to separate them within the body cavity. As a result, the risk of malignant tissue spreading and the risk of recurrence associated therewith is significantly reduced.

The invention discloses a personalized preoperative risk assessment method for a spinal tumor resection operation, and the method comprises the steps: carrying out the standardization processing of features extracted from the case data of a patient and the corresponding operation plan data, and obtaining the processed features; the method comprises the following steps: preprocessing medical image data to obtain preprocessed data, performing tumor segmentation on the data through a three-dimensional attention U-Net network to obtain a tumor voxel-level probability graph, and calculating a tumor volume; obtaining the type of the tumor through the preprocessed data, the double-flow deep network and the type discrimination network; respectively carrying out standardization processing on the type, the tumor volume, the extracted wettability score and the tumor position grade to form a third feature; obtaining basic weights of the processed features and the third features from a historical database, and then dynamically adjusting the basic weights to obtain a target weight; and performing weighted summation on the target weight, the processed feature and the third feature to obtain a risk score, and matching the risk score with a preset risk score to obtain a preoperative risk assessment level.

The invention belongs to the technical field of biomedicine, and particularly relates to a non-small cell lung cancer tissue discrimination model based on differential metabolite combination as well as a construction method and application of the non-small cell lung cancer tissue discrimination model. The differential metabolite combination is composed of lactic acid, phosphoethanolamine, decenoyl carnitine and symmetric dimethylarginine or composed of xanthine, phosphoethanolamine, N-acetyl aspartic acid, decenoyl carnitine and symmetric dimethylarginine, and the determination model establishment method comprises the following steps: collecting and treating a lung cancer tissue sample, carrying out UPLC-HRMS detection, carrying out compound identification, and carrying out quantitative determination. Differential metabolites are screened, key differential metabolites are selected through an LASSO method, the performance of all models based on the key differential metabolites is tested, and the selected optimal model is a logistic regression model. The logistic regression discrimination model based on four or five differential metabolites can effectively distinguish non-small cell lung cancer tumor tissues and normal tissues, and the accuracy, the sensitivity, the specificity, the F1 fraction and the AUC are all greater than 0.8. The model has a small quantity of metabolites, and shows the potential of assisting in clinical detection of non-small cell lung cancer tissues and the potential of assisting surgeons in determining a tumor excision range.

The invention discloses application of timosaponin AIII in preparation of a curative effect enhancer for CAR-T cell therapy and a product for overcoming drug resistance. The invention proves that TAIII is an allosteric inhibitor of an adenosine A2A receptor, and blocks a downstream signal channel through allosteric combination with A2AR, so that expression of a transcription factor FoxP3 is inhibited, Tregs in a CAR-T product is selectively cleared, immunosuppression of the Tregs on effector T cells is relieved, meanwhile, the proportion of central memory T cells is increased, and amplification, durability and cytokine secretion functions of the CAR-T cells are enhanced. The invention further provides a CAR-T cell composition containing the TAIII, and the TAIII and the CAR-T cells are combined or used as a pretreatment agent, so that the tumor removal capability can be remarkably enhanced, and recurrence after treatment can be effectively prevented. The invention provides a safe and effective new strategy for enhancing the anti-tumor activity of the CAR-T cells and overcoming the drug resistance of the CAR-T therapy.

Systems, methods and apparatus are provided through which a tumor resection planning tool in mixed reality comprises apparatuses for image registration, synchronous navigation through fused datasets, segmentation and labeling of surgery-related structures, manual correction of segmentation results, and a browser-based tool for clinical validation. In some implementations the tumor resection planning tool generates a step-by-step surgical tumor resection plan adaptable to organs such as liver, pancreas, lung, and brain. In some implementation the tumor resection planning tool displays segmented structures as 3D polygonal objects with customizable textures, transparency, and color. Risk margins offset from tumor surfaces are visualized with user-defined values. In some implementations vessel clip plan tool(s) simulate post-resection blood flow. Users can create, modify, and share resection plans, dividing organ structures based on user-defined plans. In some implementations vessel clip plan tool(s) enables a mixed reality shared experience for remote discussion of surgery plans among tumor board members.

Methods and systems for determining recurrence of a tumor in a subject using mutational profiles derived from cell-free DNA obtained concurrently with or prior to tumor resection and integrating mutational profiles from the resected tumor to enhance classification models. Low-depth whole-genome sequencing data can be used to obtain a variety of molecular profiles, including genetic and epigenetic profiles, from tumor tissue and blood samples obtained after the tumor is resected from the subject. The methods may also comprise using a classifier trained to recognize mutational profiles from subjects exhibiting minimal residual disease (MRD) to determine whether a tumor recurred in a subject.

The invention discloses a glioma operation boundary identification marker and application thereof. The invention confirms that SERPINA3 can be used as a marker for identifying a glioma invasion boundary for the first time, can effectively assist operation planning and tumor excision before or during glioma operation, improves the accuracy of operation excision, provides an effective molecular tool for clinical diagnosis and treatment of glioma, and has a remarkable application prospect.

The invention belongs to the field of medicines, and discloses application of macastine B in preparation of anti-inflammatory, repair-promoting and relapse and metastasis-resisting medicines after liver cancer operation. The invention discloses an application of macastine B in preparation of a medicine for recovering a liver cancer patient after partial liver resection. The macaxantin B can promote liver function recovery, reduce the level of inflammatory factors of liver tissues and serum species, and reduce the tumor recurrence rate and the tumor visceral metastasis rate after tumor excision after an orthotopic liver cancer surgical operation, and compared with simultaneous administration of a liver protection drug and an anti-tumor drug, the macaxantin B has the advantages that the liver metabolism burden is reduced, and the curative effect is improved. And a novel drug treatment choice is provided for disease management of a liver cancer patient in a perioperative period. The invention discloses a medicine for promoting postoperative recovery of an orthotopic liver cancer surgical operation. The medicine comprises an effective therapeutic dose of macastine B and pharmaceutically acceptable auxiliary materials.

A system and method is provided using a healthy side of a brain as tractography quantification standard in surgical planning. Tools are used to compare tractography in the pathological (ipsilateral) hemisphere to the contralateral hemisphere. The tool identifies bundles in the ipsilateral and contralateral hemisphere using surgical planning software that includes an auto-segmentation feature, and provides a ratio of their symmetry, and metric comparison. This gives users a more objective and clinically relevant way of interpreting the results of diffusion quantification. It also provides a metric that can be compared longitudinally as a hemisphere recovers after tumor resection, and brain symmetry is restored.

This invention relates to the field of medical device technology, specifically disclosing a tumor resection device, including a resection mechanism, a body, a handle, a drive mechanism, a transmission mechanism, and an adsorption mechanism. The handle, body, and resection mechanism are sequentially connected. The drive mechanism is installed inside the handle, and the transmission mechanism is installed inside the body and connected to the drive mechanism and the resection mechanism. The drive mechanism drives the resection mechanism to perform tumor resection via the transmission mechanism. The adsorption mechanism is installed inside the handle and body, and when the resection mechanism removes the tumor, the adsorption mechanism removes the removed tumor. The tumor resection device has an elongated structure, and the maximum outer diameter of the cross-section of the tumor resection device is less than or equal to 10 mm. This invention's resection mechanism removes the tumor through the adsorption mechanism, effectively reducing the wound, alleviating patient pain, and lowering surgical risks.

The application discloses a kind of biomimetic 3D printing hydrogel scaffold and its preparation method and application, belong to medical instrument technical field.The biomimetic 3D printing hydrogel scaffold includes 3D printing hydrogel scaffold and in 3D printing hydrogel scaffold surface imitating mussel catalytic coating;The biological ink of 3D printing hydrogel scaffold includes methacrylated gelatin, calcium ion pre-crosslinking sodium alginate, dendritic cell-derived exosome loaded with STING agonist and methacrylated modified osteogenic growth peptide;Imitate mussel catalytic coating is by polydopamine layer and the dopa-manganese metal polyphenol network nanoenzyme loaded on the surface of polydopamine layer jointly constitute.By the synergistic effect of each component, effectively solve the technical problem that existing scaffold lacks time sequence treatment mechanism, realize the dual effect of tumor removal and bone defect repair in bone metastasis tumor treatment.

The present invention provides methods for detecting and predicting minimal residual disease in a subject who has undergone tumor resection surgery. Method of the invention utilize a personalized cutoff for determining the likelihood for MRD. In some embodiments, the cutoff is determined on a patient-specific basis and may be used in subsequent assays to analyze samples, evaluate MRD, select therapeutics, and / or evaluate therapeutic efficacy.

The present invention relates to the field of medical device technology, and proposes a tumor stripper, comprising a handle, the handle comprising a gripping rod, an adjustment slot being provided in the middle of the gripping rod, a tensioning assembly being fixedly installed in the middle of the adjustment slot, an adjustment assembly being fixedly connected to the front end of the handle, a stripping mechanism being movably installed inside the adjustment assembly, stripping lines being connected to both ends of the stripping mechanism, the stripping lines being passed through the adjustment assembly and connected and fixed to the tensioning assembly, a drainage tube being further connected to the bottom end of the stripping mechanism, a drain being fixedly installed on the drainage tube passing through the adjustment assembly. By movably installing the stripping mechanism at the upper end of the handle through the adjustment assembly, the engagement of the toothed ring with the gear allows the stripping mechanism to rotate along the connector by simply rubbing the dial with the fingers holding the gripping rod, thereby achieving micro-adjustment of the angle of the stripping mechanism, facilitating adjustment of the stripping according to the specific location of the tumor during stripping, and making tumor removal more complete and convenient.